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1. Different kinds of networks
For any attempt to describe, analyse and simulate living 
systems, we have to acquire a comprehensive knowledge 
about their components and, even more importantly, their 
relations and interactions. If we are successful in doing so, 
we may be able to understand the underlying rules how the 
corresponding systems are organized. There were deserving 
early attempts to develop systematic approaches, for instance 
by applying the principles of cybernetics and systems 
theory onto biological systems, thus laying ﬁ rst theoretical 
foundations, but real success of these efforts had to await the 
advent of genomics and other omics mass data. These data 
reﬂ ect different aspects of biological systems organized at 
different levels of complexity. For instance, genes as one-
dimensional strings of nucleotides (or their symbols) may 
constitute a conceptionally simple network of functional 
interactions. More sophisticated are the interaction or 
reaction networks at the molecular level, since the number
of components involved is 1–2 orders of magnitude higher 
(105 – 106 proteins, including splice variants, posttranslational 
modiﬁ cations and complexes, versus 104 genes). As a 
consequence of the complex three-dimensional structures 
and highly versatile functions of proteins, the way how their 
interaction networks are organized also includes much more 
variable patterns in forming numerous branching and cyclic 
constructs (e.g. feed-back, feed-forward, bi-fan, etc.), which 
altogether form rather complex circuits. And even higher is 
the potential complexity of cell-cell interactions through all 
kinds of intercellular communication mechanisms.
1.1 Intercellular networks
In a multicellular organism, the function of distinct organs, 
tissues and cell types have to be precisely coordinated to 
ensure proper functioning of the whole system (organism) 
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and its proper responses to external stimuli (see, for instance, 
Nussey and Whitehead 2001, for a general introduction). 
Any trigger that requires concerted action of more than one 
cell type, be it a physical, chemical or biological one, is then 
forwarded through a cascade of signalling events involving 
different cells. These cascades may be organized in a way 
to diversify and amplify the signal or to constitute parallel 
signal transmission channels which may render the whole 
system robust against errors. Starting with the original cell 
(type) which acted as sensor of the original trigger, a series 
of molecular communication steps constitutes a complex 
pathway which we can imagine as a bipartite directed graph 
consisting of molecular messengers and the involved cells 
as node classes (ﬁ gure 1). The entry and the internal cell 
nodes of this pathway (or network) act as donors emitting 
(secreting) the molecules (hormones, cytokines, growth 
factors, or other messengers) required for further processing. 
The internal cell nodes initially act as acceptors by receiving 
a signal, before turning into donors themselves. The exit 
points of each pathway are ﬁ nal acceptor or target cells in 
which deﬁ ned processes are initiated which give rise to the 
speciﬁ c physiological response to the initial signal.
There are different kinds of messenger molecules, 
genome-encoded as well as non-genome encoded ones. 
The ﬁ rst group, peptide and protein hormones as well as all 
cytokines, growth factors and many others, are encoded by 
individual or multiple genes, in case they are multi-subunit 
proteins. Interestingly, by far most of them require more or 
less extensive posttranslational processing, at least by leader 
peptide cleavage, or, in many cases, by clipping of a longer 
precursor polypeptide into a series of biologically active 
oligopeptides.
Acceptor cells are primarily deﬁ ned by expression of 
the respective receptor molecules. Inside all acceptor cells, 
speciﬁ c signal transduction (ST) pathways are triggered by 
the incoming signal. They may aim at any of the known 
targets of ST pathways, i.e. at: (i) transcription factors (TFs) 
in order to change the genetic program of this cell; (ii) 
metabolic enzymes to adapt the metabolism of the cell; (iii) 
the secretion machinery in order to control the release of the 
next wave messenger molecules; (iv) structural components 
of the cell to change the overall cell morphology.
In those acceptor cells which turn into donor cells (i.e. 
internal nodes), process (i) is obligatory if the next-wave 
Figure 1. Foundation scheme of a hormonal as example for any intercellular network (Potapov et al 2006). An original stimulus triggers 
the primary donor cell to secrete a hormone A which stimulates an acceptor cell to release hormone B, thereby turning into a donor cell 
itself. At the end of the cascade, ﬁ nal acceptor or target cells undergo some metabolic, genetic or structural changes to exert the required 
physiological effect.
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messenger molecule is genome-encoded, e.g. a peptide 
hormone. If the induced messenger is not genome-encoded, 
e. g. a steroid hormone, either process (i) or (ii) has to 
be activated, for stimulating the expression of metabolic 
enzyme genes and, thus, to its de novo synthesis, or for 
activating already existing enzyme molecules, respectively.
Each of these subsequent events is subject to a different 
kind of network, with speciﬁ c distinguishing features, some 
of which shall be described in the following.
1.2 Signal transduction pathways
In highly compartmentalized eukaryotic cells, any external 
signal that is to provoke speciﬁ c cellular effects has to be 
transduced to its target compartment. Only very few of them 
are mediated by molecules that are allowed to enter the cell 
themselves and target their docking molecules, and even 
these (some small hydrophobic molecules) may require 
some cellular carriers for being transported to, e.g. the 
nucleus where they may bind a nuclear receptor (see, e.g. 
Siegenthaler 1996; Li and Norris 1996; Nettles and Greene 
2005).
The majority of extracellular ligands, in particular 
polypeptides and proteins, but also some smaller molecules, 
do not enter a target cell but require a membrane receptor 
to bind to and initiate a more or less complex signal 
transduction cascade. These cascades may require a series 
of (reversible) binding and de facto irreversible reactions, 
usually enzymatic modiﬁ cations of target molecules. 
Generally, each reaction generates the ‘active’ component 
of the following step, usually the active catalyst of the 
subsequent reaction (ﬁ gure 2A). This way, the signal is 
transmitted (‘transduced’) through a number of steps, 
each having the potential to amplify the signal in an 
enzymatically catalyzed reaction, to diversify the signal 
due to low substrate speciﬁ city of the catalyst, to branch off 
the pathway by leading to more than one active products, to 
enable other pathways to cross-regulate (“cross-talk” to) it, 
and to specify the transmitted signal by requiring additional 
ones to come in and combine with it.
ST pathways and networks are well represented by 
directed graphs. As shown in ﬁ gure 2A and described 
previously, we have proposed to represent them as bipartite 
directed graphs, with molecules and reactions as the two 
node classes (Schacherer et al 2001). It is important to 
differentiate between ST and protein-protein interaction 
networks, the latter being undirected and comprising any 
kind of interaction, independent of the functional purpose. 
Figure 2. Typical generalized topology of a signal transduction path (A) and a metabolic path (B). In the former, an incoming signal (S
1
) 
binds to a receptor, thereby generating the ‘active’ component (usually, the catalyst) of the next step, and so on. In contrast, in a metabolic 
path (B), an incoming substrate S
1
 is converted by a number of largely pre-existing catalysts into a ﬁ nal product S
6
. While in the signalling 
path, the initiating molecule S
1
 and the resulting molecule C
6




 in the 
metabolic path share at least some of their atoms.
Edgar Wingender et al172
J. Biosci. 32(1), January 2007
Moreover, ST pathways have to comprise also non-
proteinaceaous components such as second messengers like 
inositol-1,4,5-trisphosphate (IP3), diacylglycerol (DAG) or 
calcium ions.
1.3 Metabolic networks
Like ST pathways, metabolic pathways or networks consist 
of sequences of catalyzed reactions. However, unlike ST 
pathways, the active catalysts are usually preexisting and 
hand over the product of the previous step towards the next 
one. The ﬁ nal product has at least some atoms in common 
with the input substrate (ﬁ gure 2B) which also clearly 
differentiates metabolic from ST pathways. Thus, while 
metabolic pathways represent generally the transformation 
of matter, ST pathways transfer signals, i. e. information.
Catabolic as well as anabolic pathways comprise the 
breakdown of complex and the synthesis of more complex 
cellular substances. However, in today’s general language, 
metabolic pathways are most commonly understood as the 
network of those reactions that convert small molecules into 
each other.
Different representations of these metabolic (or 
‘biochemical’) pathways may exhibit the complete chemical 
reaction equations, or just the sequence of most important 





O, or ATP). The catalysts are usually 
assigned to the reaction equations, frequently as enzyme 
code numbers according to the international enzyme 
catalogue (EC numbers) (as done, for instance, by the 
typical KEGG maps; Kanehisa et al 2006). 
An alternative would be a more enzyme-centric view 
which displays the series of enzymes as they appear in a 
metabolic path, connected by product-educt relations of 
the corresponding reactions. The resulting pathways can 
be transformed into a genetic network if the enzymes are 
replaced by the genes which encode them. This view can 
also be obtained with the aid of KEGG or with the enzyme 
database BRENDA (Schomburg et al 2004).
1.4 Gene regulation networks
Genetic networks represent abstract functional relations 
between genes. Nothing is said about the kind of functional 
interaction between the genes linked in such a network. This 
is different in a gene regulatory, or transcriptional, network. 
In such a transcription network (sensu strictu), the nodes 
represent genes encoding transcription factors (TFs), and the 
edges stand for the transcriptional regulation of these genes 
by the encoded transcription factors.
Unfortunately, the available experimental information 
about veriﬁ ed transcription factor binding sites (TFBS) 
or other data about TF-target gene relations is still scarce 
when we consider mammalian systems. A rough estimate 
suggests that we have knowledge of about only 1% of all 
TFBS that we may expect to exist in the human genome: 
Assuming a number of ~30,000 genes in the human genome 
with just 6 TFBS per gene (unpublished conservative rough 
estimate from TRANSFAC annotations of promoters that 
have been studied in-depth), we would expect a lower limit 
of 240,000 TFBS in the whole genome. This is an extremely 
conservative assumption since it leaves aside the existence 
of multiple promoters and enhancers for many genes, 
and the variability of TFBS arrays under different spatio-
temporal cellular conditions. The TRANSFAC database (see 
below for details) documents about 2500 human TFBS, or 
about 1% of what we could expect.
The picture does not change signiﬁ cantly if we include 
more recent high-throughput data obtained by chromatin 
immuno-precipitation of bound genome regions and 
subsequent microarray hybridization (ChIP-chip; Ren et al 
2000). These data give no precise information about exact 
location and sequence of the TFBS, but just indicate a region 
of several hundred base pairs in which a TFBS is located. 
Moreover, in many cases the factor under study seems not to 
bind directly to this region but rather in an indirect manner, 
mediated through protein-protein interactions with another 
TF – a mechanism which provides one possible explanation 
for the lack of a clear consensus match in many of the 
isolated sequences. Nevertheless, these studies provide 
useful additional TF-target relations, though not to an extent 
that would signiﬁ cantly change the numbers estimated 
above.
Thus, for a comprehensive transcriptional network 
analysis, we depend on reliable methods for predicting 
TFBS and, thus, TF-target gene relations. We will refer to 
these methods in greater detail further. 
2. Corresponding database sources
Careful analysis of the intrinsic features of the individual 
networks described above led to the development of 
a number of databases which will be described in the 
following
2.1 EndoNet: An information resource about
endocrine networks
We have recently described a new database on endocrine 
networks (EndoNet) which provides information about 
hormone and hormone receptor molecules (Potapov et al 
2006). For the previous, the location (organ / tissue / cell 
type) is documented by making use of the Cytomer ontology 
(see below) for deﬁ ning hormone donor cells. For the latter, 
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the tissue in which they are expressed is given as well, since 
this deﬁ nes hormonal acceptor cells. The conceptual scheme 
of the database is shown in ﬁ gure 3. 
The major aim of providing information about molecules 
(hormones and their receptors) is not to duplicate the work 
done by, e.g. Swiss-Prot or HumanPSD, though both these 
databases are extensively cross-linked by EndoNet entries 
(see below for further information about HumanPSD). 
Instead, EndoNet is devoted to the task describing the 
molecular entities which are the active components in the 
hormonal network, rather than to refer to any particular 
gene product(s). In other words, for oligo- or polypeptide 
hormones that have been produced from larger precursors 
by extensive processing, those mature peptides are 
considered that have been proven to act as extracellular 
signal molecules, here: hormones. Similarly, for those 
hormones and receptors that consist of several subunits, 
the corresponding EndoNet entry refers to the whole active 
complex, but explains its subunit structure and links to the 
corresponding protein and gene entries in other databases. 
The present content of EndoNet is summarized in table 1. 
Though presently conﬁ ned to hormonal networks, the basic 
concept of EndoNet allows to model any kind of molecular 
cell-cell-interaction and will be expanded correspondingly 
in future.
The cellular origin of hormones and location of receptors 
is described by referring to Cytomer. This is a relational 
database on human and mouse anatomical structures, 
tissues, cell types, physiological systems and developmental 
stages from which an OWL-based ontology has recently 
been derived (Michael et al 2004).
Although EndoNet’s view of the participating cells is 
allowing them to play the role of both acceptor and donor 
simultaneously, the internal processes which interlink a 
cell’s input and output are not part of its contents. Rather, 
the signal transduction cascades that forward the hormonal 
signal to the proper intracellular targets are part of our 
signal transduction database, TRANSPATH. As for relevant 
metabolic pathways, we plan to give references to the KEGG 
database in near future.
2.2 TRANSPATH: An information resource for
signalling pathways and their pathological
aberrations
In TRANSPATH, signalling pathways and networks are 
organized as bipartite directed graphs (Schacherer et al 
2001). Both classes of nodes, molecules as well as reactions, 
are subject to complex hierarchies (Choi et al 2004; Krull 
Figure 3. Conceptual schema of the EndoNet database (Potapov et al 2006). Donor cells D act on acceptor cells A through molecules 
(here: hormones) that are transported via a certain medium, usually blood. Both cells are assigned to the Cytomer hierarchy of tissues and 
cells. In intracellular pathways through which an acceptor cell may be turned into a donor cell for another kind of hormone is modelled in 
other databases, e.g. TRANSPATH or KEGG.
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et al 2006). Polypeptide molecules are given as individual 
splice variants, at the level of ﬁ nest granularity, summarized 
by all molecules encoded by one gene (called ‘isogroup’), 
forming ‘families’ at a number of levels of increasing 
abstraction. These molecular hierarchies are implemented 
for each species represented in the database (mainly 
human, mouse and rat), as well as for a species-independent 
representation of ortholog groups. These hierarchies 
are orthogonal to a systematic and, again, hierarchical 
representation of posttranslational modiﬁ cations (PTMs) 
of polypeptide entries on each level. Besides, non-genome 
encoded molecules to which species-assignment obviously 
does not apply (e.g. second messengers), are also included 
in the database. 
Reactions are given on three principally distinct levels, 
called “evidence level”, “pathway level” and “semantic 
projection” (ﬁ gure 4). The ﬁ rst two provide individual 
pathway steps as chemical reaction equations. The 
difference is that the “evidence level” exactly refers to 
what has been shown in the cited publication, including 
species-speciﬁ city of the participating molecules (in many 
cases of heterogeneous origin) and some redundancies 
reﬂ ecting different aspects of the same pathway step such 
as physical interaction of an enzyme with its substrate and 
the subsequent modiﬁ cation reaction, if both have been 
evidenced separately. These ﬁ ndings have been summarized 
and abstracted from the species origin of the individual 
molecules when proceeding to the pathway level. However, 
they are still given in a ‘mechanistic’ view, i.e. as chemical 
reaction equations. This changes when the corresponding 
reactions are projected to the ‘semantic’ level. Here, we 
focus on the important key components that actively process 





 as well as the exact PTM and complexing status 
of the key components.
Presently, TRANSPATH has 54,340 molecule and 95,150 
reaction entries. Many of the ‘interaction’ and ‘binding’ 
reactions have been incorporated from HumanPSD (Human 
Proteome Survey Database).
The Proteome databases are a collection of databases 
which represent the complete Proteomes of a number of 
organisms. The ﬁ rst was the Yeast Proteome Database 
(YPD) for Saccharomyces cerevisiae with comprehensive 
protein reports for all known yeast proteins (Costanzo 
et al 2001). It was complemented later on by PombePD 
(Schizosaccharomyces pombe proteins), WormPD (on C. 
elegans proteins), and MycoPathPD (pathological fungi
such as Candida albicans). Again later on, HumanPSD
and GPCR PD were added for covering the whole space 
of human, mouse and rat proteins and, with some special 
features, on their G-protein coupled receptors (Hodges et al 
2002). One of the most prominent features of HumanPSD is 
its extensive annotation of expression patterns and disease 
association of these proteins. We come back to this when 
describing some of our recent tool developments below. 
Detailed annotation of protein functions in HumanPSD 
resulted in a signiﬁ cant contribution to GO development 
(Harris et al 2004) and has enabled improved analysis 
of differentially regulated genes revealed by microarray 
experiments (Johnson et al 2005). Moreover, protein-protein 
interactions (not necessarily physical ones) are extensively 
documented in HumanPSD and linked to an interactive 
visualizer.
At the bottom end of most signalling cascades are 
modiﬁ cations of transcription factors changing their 
activities to activate or repress transcription of speciﬁ c sets 
of genes. These TF-target gene relations have been mostly 
incorporated from the TRANSFAC database, but detailed 
information about the TF binding sites involved were 
omitted.
Table 1.  Summary of database contents (status June 2006).





Hormone molecules        369       369
Receptor molecules        548       548
Tissues/cells        224       224
TRANSPATH
Molecules   54,340
Reactions   95,150
TRANSFAC
Factors      8406     1660
Sites   17,905     2500
Factor-site interactions   22,447
Genes   14,582  10,811
Matrices        811
TRANSCompel
Composite elements        421
Genes        274       123
Interactions      1898
TRANSPro
Promoter sequences 155,989  55,633
PathoDB
Mutated factors   12,178  12,168
Mutated sites          75         75
HumanPSD
Proteins   50,692   19,456
GO assignments 305,578 116,782
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2.3 TRANSFAC: An information resource about
transcriptional regulation
Since its very beginning as a mere tabulated collection of 
published data in 1988 (Wingender 1988), TRANSFAC 
has been a compilation of eukaryotic TFs, their genomic 
binding sites (TFBS) and DNA-binding proﬁ les. In addition, 
a classiﬁ cation scheme of transcription factors according 
to their DNA-binding domains was developed (Wingender 
1997) and reﬁ ned over the years (Stegmaier et al 2004). 
More recently, a new ‘table’ comprising ChIP-chip data 
has been added (Matys et al 2006). It provides presently 
information about 3841 DNA-fragments interacting with, so 
far, 8 different TFs.
Since TRANSFAC and its structure became a de facto 
standard in the ﬁ eld, it offers itself as a platform to host also 
contents of third-party data if they conform to the quality 
standards of TRANSFAC. Thus, information about 1440 
Arabidopsis thaliana transcription factors have been taken 
over from the DATF database (Guo et al 2005). These data 
have been generated by an Arabidopsis TF proteome project 
at Peking University (Gong et al 2004). Similarly, 899 
genomic site entries have been imported from the Drosophila 
DNase I footprint database (Bergman et al 2005).
There are a couple of smaller, specialized databases 
in the periphery of TRANSFAC which provide data on 
particular aspects of gene regulation. Among them is the 
TRANSCompel database on composite elements (CEs), 
i.e. combinations of single TFBS which together provide 
particular function on the regulation of the associated gene. 
The usually synergistically, sometimes antagonistically 
acting TFBS that constitute CEs have generally been very 
carefully characterized with regard to their function. The 
exact experimental evidence for each CE is documented in 
the database.
In addition, the database module PathoDB provides 
information about pathologically relevant mutations that 
have been found in TF-encoding genes or in TFBSs, together 
with proper genotype and phenotype information (Matys et 
al 2006). We are presently working on an integrated view 
of these data together with those that similarly describe 
mutations in genes of signalling components (PathoSign) 
(Krull et al 2006) and with those of the Human Gene 
Mutation Database, created and maintained by Cardiff 
University (Stenson et al 2003).
The fourth component of the TRANSFAC suite of 
databases is the promoter database TRANSPro which 
collects sequences around documented transcription start 
sites (TSSs), making use of Eukaryotic Promoter Database 
(EPD) (Schmid et al 2006), DBTSS (Suzuki et al 2004; 
Yamashita et al 2006) and Ensembl (Hubbard et al 2005) 
annotation of TSSs (Chen et al 2006). The latest addition 
Figure 4. Three-level model for signalling reactions in the TRANSPATH database. The “evidence level” represents as many experimental 
details obtained from the original publications as possible, while the “pathway level” summarizes this information and ‘chains’ reactions 
that have been proven to sequentially occur in a certain cellular environment. Reactions on either level are mechanistically represented, as 
biochemical reaction equations, whereas the “semantic projection” focuses on those signalling components that are actively involved in 
transmitting the signal. Expanded pathways and networks can be computationally reconstructed on either level.
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also considers TSSs reported by the Fantom consortium 
(Maeda et al 2006). The user may deﬁ ne the range of 
interest for his/her research within a –10,000 and +1000 
nucleotides around these TSSs of many human (55,633 
promoters), mouse (69,446), rat (3595) and Arabidopsis 
thaliana (27,315) genes. TRANSPro has recently been 
combined with information to tissue-speciﬁ cities of the 
expression of the genes which they control. This novel 
tissue-speciﬁ c promoter database (TiProD) allows to select 
sets of promoters according to their tissue-speciﬁ city, but 
also with regard to any gene ontology (GO) category (Chen 
et al 2006).
Finally, S/MARt DB is a database on scaffold / matrix 
attached regions of eukaryotic genomes which will not be in 
the further focus of this review (Liebich et al 2002).
3. Tools for predictions
One of the goals of bioinformatics is certainly to contribute 
to reveal the rules behind the huge amount of  facts which 
we have collected in our databases. These rules qualify an 
exact science if they prove to have predictive power, i. e. to 
predict features and/or behaviour of a certain system. If so, it 
is of general interest to have them implemented in software, 
preferably through a Web interface, so that the community 
can apply it for further scientiﬁ c progress. 
3.1 Analysis of transcription regulatory regions
On the different levels of biological processes described 
here, those deﬁ ned on the lowest complexity level (the 
genomic DNA sequence) can be most reliably predicted 
so far, though this is still far from perfection. For instance, 
many approaches for identifying individual transcription 
factor binding sites have been developed over the last 15 
years, which to review is not the appropriate place here. One 
of them has been developed by ourselves and implemented 
into the program Match which comes along with the 
TRANSFAC database (Kel et al 2003). It uses the positional 
frequency matrix collection of the database and works 
with different sets of thresholds that have been optimized 
individually for each matrix and either minimize the number 
of false positive or of false negative predictions, or the error 
sum of both of them. The user can override and re-deﬁ ne 
these default values and compose own proﬁ les, comprising 
only those matrices that are of the user’s special interest and 
their individually deﬁ ned thresholds. In addition, a number 
of pre-deﬁ ned proﬁ les for, e.g. tissue-speciﬁ c TF sets and 
their matrices are available as well. 
Compared with the outdated approach of simple 
string matching using known binding sequences for the 
identiﬁ cation of potential TFBS, the matrix approach 
introduces much more ﬂ exibility and generally provides 
higher sensitivity at the same speciﬁ city. However, its 
general assumption is that the individual positions are 
independent from each other which may be true in most, but 
certainly not in all cases. To accommodate these concerns, 
variable order Markov chains and Bayesian networks have 
been developed and successfully applied to prokaryotic 
sigma-70 binding sites in Escherichia coli (Ben-Gal et al 
2005); a corresponding Web tool is available (http://pdw-24.
ipk-gatersleben.de:8080/VOMBAT/). Our own approach 
was to combine matrix with string matching, making use 
of the variability a positional frequency matrix provides as 
well as of the knowledge about patterns that are working 
in a real genomic environment (P-Match) (Chekmenev et 
al 2005). The approach has been proven advantageous for 
predicting binding sites of many TF, though certainly not 
all, in particular in the range of high sensitivity (low rate 
of false negative hits), which is usually accompanied by a 
drastic increase in the false positive matches (decrease of 
speciﬁ city) and which could be largely avoided by the P-
Match algorithm (Chekmenev et al 2005). 
Another method to increase the reliability of single site 
prediction which gains increasing popularity is phylogenetic 
footprinting (Tagle et al 1988). In most cases, this is done by 
primate-rodent (e.g., human-mouse) comparison and it has 
recently been reconﬁ rmed that the approach has its validity, 
but on average leads to a false-negative rate of about one 
third (Sauer et al 2006). Interestingly, the binding sites of 
different transcription factors largely differ in the degree of 
their sequence-conservativity, indicating that this method 
should be applied with caution.
Nevertheless, all the existing methods for the prediction 
of individual TFBS have severe limitations. As an emerging 
picture, it seems that the required speciﬁ city for ﬁ ne-tuned 
transcriptional regulation in a higher eukaryotic cell is 
achieved by the context of a number of TFBS, combining 
to (usually binary) composite elements and more complex 
promoter modules. To identify a speciﬁ c combination of 
(predicted) TFBS that may be functionally relevant in a 
given set of promoters means, we have to search for speciﬁ c 
TFBS types, their scoring, relative (to each other) and 
absolute (to the respective TSS) distance correlation and 
mutual orientation. That requires optimization within a large 
search space which we recently have suggested to do by 
using a genetic algorithm which has been implemented in a 
tool (CMA, composite module analyzer) (Kel et al 2006a).
3.2 Pathway reconstruction
As described above (§2.2), the TRANSPATH database 
harbours a huge number of signal transduction reactions on 
different abstraction levels. Many of them have been pre-
compiled and are labelled to belong to certain ‘canonical’ 
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pathways, such EGF or HIF-1alpha pathway. However, 
the individual reactions can be combined to a much larger 
number of (potential) pathways and networks when we 
link those that produce a certain state as result with those 
that start from the same state. This is achieved by the 
tool PathwayBuilder, which is part of the TRANSPATH 
database. It can easily end up with gigantic maps of predicted 
networks which are hard to visualize, and impossible to 
think out beforehand.
Moreover, many of these pathways may be “false 
positively” predicted ones, for instance due to the fact that 
some reactions may have been shown under pure in vitro 
conditions and will hardly occur in a cellular environment. 
To cope with this, we have developed an algorithm and 
implemented it in PathwayBuilder which during pathway 
reconstruction gives priority to those sequences of reactions 
which have been experimentally shown to follow each other 
in a certain cellular environment. The user can assign a 
special preference to these ‘chains’ of reactions by adapting 
the cost function of the length of the shortest paths in the 
reconstructed network (Kel et al 2006b).
The Pathway Builder has been re-used also for visualizing 
transcriptional networks as they can be retrieved from the 
TRANSFAC database (§2.3).
3.3 Analysis of expression data
Attempts to obtain insights into a certain biological process 
frequently make use of new high-throughput technologies 
such as microarray-based comparison of the transcriptomes 
of different cells. Usually, the resulting sets of affected 
genes, either up- or down-regulated, and their respective 
products are mapped onto known pathways or networks, e.g. 
metabolic networks as they are represented in the KEGG 
database, or signalling networks from TRANSPATH. The 
information obtained from this kind of approach may give 
answers to the question, which functions of the cell are 
affected by the conditions under consideration (“downstream 
analysis”; ﬁ gure 5).
However, when considering the causes that have led 
to the observed changes and thus trying to generate an 
explanatory model, we have to analyse the regulatory 
Figure 5. General strategy of gene expression analysis by the ExPlain system. A set of induced genes which may have been obtained 
from a microarray experiment (central box), is translated into its products and mapped onto, e.g., signal transduction pathways as they are 
represented in the TRANSPATH database (grey ovals). Independently, the system retrieves the promoter sequences, analyses them for 
potential transcription factor binding sites (TFBSs, red rectangles), constructs promoter models by comparing these promoters with those 
of a control set, and predicts the relevant transcription factors. Pathway analysis may reveal potential key nodes that controlling the set of 
genes under study (top part). In addition, a promoter database such as TRANSPro can be screened with the obtained promoter model for 
additional genes that belong to this set of co-regulated genes (blue rectangles). Their products (blue ovals) can be mapped on the available 
pathways as well.
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mechanisms of the up- and down-regulated genes. Usually, 
the available experimental information for this is scarce so 
that we depend on reliable predictive methods to analyse the 
corresponding promoters, and to come up with “promoter 
models”, i. e. sets of TFBS with a certain scoring, order, 
orientation and distance correlation. Once a promoter model 
has been established, we can hypothesize the transcription 
factors involved, and can derive the signalling pathways 
upstream of them controlling their activities. If we are lucky, 
we may ﬁ nd a node in the network where the different paths 
which we follow upstream converge, and which therefore 
may be candidates for mastering the observed set of genes 
and, thus, the process under consideration (ﬁ gure 5). Note 
that the gene of such a key node itself is not necessarily 
upregulated; sometimes, it is even not a genome-encoded 
node in the signalling network.
With a promoter model at hand, we may also go back 
to the promoter database and identify additional genes that 
might belong to the same cluster of co-regulated genes, 
although they have not been observed in the experiment. 
Their induction/repression may have been masked for 
whatever reason from observation or analysis, or the 
appropriate probe was missing from the array used. 
We have now combined most of our previously developed 
databases and tools to a comprehensive platform for 
analysing gene expression data in both down- and upstream 
direction (ExPlain). Raw data about induction/repression of 
gene expression rates can be uploaded as text or Excel spread 
sheets, manually divided into positive and negative control 
sets, and analysed for functional clusters in terms of any GO 
category, expression proﬁ le, disease function (according to 
HumanPSD) or signalling pathway (from TRANSPATH). 
Any such deﬁ ned cluster of genes, or the whole set, may 
be subjected to an upstream analysis as outlined above. For 
this, automatized retrieval of all relevant promoters from 
TRANSPro is followed by analysis for single TFBS using 
TRANSFAC matrices and Match with any pre- or user-
deﬁ ned proﬁ le. The sets of predicted TFBS can be analysed 
further with the CMA, and the potential pathways acting on 
the suggested sets of transcription factors and potential key 
nodes are identiﬁ ed with PathwayBuilder and ArrayAnalyzer 
on the basis of TRANSPATH contents. Altogether, the 
ExPlain tool provides an interactive workﬂ ow implementing 
the scheme shown in ﬁ gure 5.
4. Applications
Proof-of-principle has been given for most of the concepts 
outlined above. For instance, the power of context-sensitive 
analysis of transcription regulatory regions was proven 
for E2F sites, which play an important role in cell-cycle 
regulation, as well as for composite elements comprising 
NFATp and AP-1 elements which are involved in T-cell 
activation-associated gene induction events (Kel et al 
1999, 2001). The same approach plus promoter module 
construction led to challenging hypotheses about the 
involvement of certain TFs in development of aggressive 
behaviour in mice (D’Souza et al 2003), and was 
successfully proven in the case of aryl hydrocarbon receptor 
target genes (Kel et al 2004). A more stringent knowledge-
based approach was used to model the promoter structure 
of genes that are involved in antibacterial cell response 
(Shelest and Wingender 2005). Linking promoter modelling 
with comprehensive pathway analysis led to interesting 
hypotheses in connection with certain disease studies, some 
of them have already been veriﬁ ed experimentally and will 
be published elsewhere (Kel et al unpublished results).
Systematic application of network topology analysis has 
been demonstrated to lead to useful results. Comparative 
analyses of the whole signalling network represented 
in the TRANSPATH database (“Reference network) as 
well as the subnetworks of insulin signalling and the p53 
network all revealed clear scale-free and modular properties. 
When conﬁ ning this analysis to the transcriptional 
network, extracted from the databases TRANSFAC and 
TRANSPATH, where the node represent TF genes and the 
edges transcriptional regulation by the encoded TFs, these 
features were conﬁ rmed. Most interesting, however, proved 
a topology parameter which has been rarely investigated 
in the past: betweenness centrality (BC). A node’s BC is 
deﬁ ned as the fraction of those shortest paths between all 
pairs of vertices that pass through this node. Nodes with 
high BC value do not necessarily have a high connectivity 
(degree) by themselves. Nevertheless, they are of key 
importance for the whole network. When we computed this 
parameter for all TF genes in the transcriptional network 
and ranked the factors according to their BC values, the top-
most ﬁ ve entities were all either tumour suppressor or proto-
oncogenes (p53, c-fos, Egr1, c-jun, WT1) (Potapov et al 
2005). Unfortunately, the overall network size is relatively 
small (121 nodes, 212 edges) due to the limited number 
of experimentally proven TFBS in TF gene promoters, 
for which reason this observation can be taken only as 
preliminary result. Presently, we make attempts to enrich the 
network by TF-target gene relations through potential TFBS 
predicted by a combined matrix-phylogenetic footprinting 
approach. 
5. Discussion
The different kinds of networks shortly depicted above and 
represented in the databases described in this contribution 
reﬂ ect some of the main organizational levels of biological 
systems. Although systems biology has usually modelled 
and investigated the behaviour of cellular systems so 
far, the advent of increasingly efﬁ cient high-throughput 
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methodologies will enable us to step beyond this borderline. 
We have to achieve a “vertically integrative” systems 
biology where we can smoothly zoom between the different 
complexity levels, from the systemic all-organism layer 
down to the nuclear (transcriptional) events in individual 
cells that play a key role in a certain physiological
process. Systems biology also includes the development 
of predictive models for the behaviour of the system under 
investigation. The complexity of the higher-level (e.g. 
physiological) systems renders it extremely unlikely that 
it will be possible to exactly describe all molecular details 
involved in a certain physiological process by ordinary 
differential equations (ODEs). Rather, we have to identify 
the essential steps, those that are subject to thorough 
molecular or genetic regulation, model these steps with the 
required precision, and keep the remainder of the network at 
a much lower granularity. Thus, identifying the appropriate 
granularity for each system model will be one of the major 
tasks when proceeding with systems biology approaches to 
systemic descriptions. A second one will be to provide the 
appropriate biological semantics that have to be connected 
to these mathematical models. To do this in a formally 
strict way, corresponding ontologies have to be developed 
and greed upon by the community. It is our very hope that 
the resources described above can contribute to both these 
important tasks.
6. Availability
Many of the databases and tools described in this article are 
freely accessible for users from non-proﬁ t organizations 
(TRANSPATH Public, TRANSFAC Public, TRANSCompel 
Public, PathoDB, Match, P-Match, CMA: http://www.
gene-regulation.de; Cytomer, EndoNet, PathoSign: http://
www.bioinf.med.uni-goettingen.de/services/; TiProD: http://
tiprod.cbi.pku.edu.cn:8080/index.html). Cytomer, PathoDB, 
TRANSFAC, TRANSCompel, TRANSPATH, are registered 
trademarks, HumanPSD, GPCR PD, PombePD, TRANSPro, 
WormPD, YPD, ExPlain, Match, and P-Match are 
trademarks of BIOBASE GmbH, Wolfenbüttel, Germany. 
HGMD is a registered trademark of Cardiff University, 
Cardiff, Wales, UK. 
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